Jefferson Davis is a veteran life science executive and transaction specialist with over 25 years’ experience in business and corporate development, research, and project financing. He has deep experience in developing and implementing business and corporate development campaigns for start-ups and Fortune 500 corporations, most recently as a senior member of Genzyme’s Corporate Development team. Jefferson has led or supported over 30 transactions with an aggregate value in excess of $1B across all major therapeutic platforms, including antibodies, small molecules, aptamers, gene therapy, vaccines and proteins. Representative transactions include the ImmunoGen-Aventis strategic alliance ($500M) and Archemix-Elan research collaboration ($350M). Prior to Extera Partners, Jefferson held senior business and corporate development roles at Genzyme, Archemix, ImmunoGen, GenVec and Eli Lilly. Jefferson received a BS in Biochemistry from North Carolina State University and MBA from Duke University.